SELLAS Life Sciences Reports Data In Completed Phase 1 Study Of Galinpepimut-S Combined With Opdivo In Advanced Malignant Pleural Mesothelioma; Primary Endpoint Of Safety And Efficacy Endpoint Met With Clinical Activity And Increased Survival Observed
Portfolio Pulse from Happy Mohamed
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) has reported positive data from a Phase 1 clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with nivolumab (Opdivo) in patients with malignant pleural mesothelioma (MPM). The trial met its primary endpoint of safety and efficacy, with increased survival observed. The median overall survival for patients treated with the combination therapy was 70.3 weeks, with 40% of patients still alive at the last follow-up. No dose-limiting toxicities were observed.
June 28, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive data from the Phase 1 trial of SELLAS Life Sciences' lead clinical candidate, galinpepimut-S, combined with Opdivo, is likely to have a positive impact on the company's stock in the short term. The trial met its primary endpoint of safety and efficacy, with increased survival observed in patients with malignant pleural mesothelioma.
Positive clinical trial results often lead to an increase in a biopharmaceutical company's stock price, as they indicate progress in the development of a potential new product. In this case, the successful Phase 1 trial of galinpepimut-S and Opdivo in patients with malignant pleural mesothelioma suggests that SELLAS Life Sciences is making significant strides in its research, which could lead to increased investor confidence and a rise in the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100